Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > J Liver Cancer > Volume 17(1); 2017 > Article
Case Report A Case of Advanced Hepatocellular Carcinoma with Long-term Post-progression Survival under Repeated Transarterial Chemoembolization after Sorafenib Failure
Jihyun Lee1, Hwi Young Kim1, Yong Jin Jung2, Tae Hun Kim1, Kwon Yu1
Journal of Liver Cancer 2017;17(1):82-87
DOI: https://doi.org/10.17998/jlc.17.1.82
Published online: March 31, 2017
  • 1,123 Views
  • 8 Download
  • 0 Crossref
  • 0 Scopus
1Department of Internal Medicine, Ewha Womans University School of Medicine
2Department of Internal Medicine, Seoul MetropolitanGovernment Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
Corresponding author:  Hwi Young Kim,
Email: hwiyoung@ewha.ac.kr

Hepatocellular carcinoma is the third leading cause of cancer related mortality worldwide. Only 30% of patients are eligible for curative surgical resection at diagnosis. For patients with advanced hepatocellular carcinoma with accompanying portal vein tumor thrombosis, Sorafenib is recommended as first-line treatment. However, survival gain from sorafenib is unsatisfactory, and there is no standard therapy for patients who are intolerable or refractory to sorafenib. Here we report a case of a 52-year-old man who initially achieved partial response after sorafenib treatment, but eventually showed disease progression and was treated subsequently with transarterial chemoembolization (TACE). Multinodular recurrence occurred, but he was treated with repeated TACE, and has survived for 4 years so far.

Related articles

JLC : Journal of Liver Cancer